Results 21 to 30 of about 212,526 (280)

Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer, 2014
R. Hendriks, S. Yuvaraj, Laurens P. Kil
semanticscholar   +3 more sources

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

New England Journal of Medicine, 2022
BACKGROUND Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL).
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya, R. Notti, J. Afaghani, B. Durham, A. Penson, Matthew T. Witkowski, Sydney X Lu, J. Bourcier, Simon J. Hogg, C. Erickson, Daniel Cui, Hana Cho, Michael Singer, T. Totiger, S. Chaudhry, M. Geyer, Alvaro J Alencar, A. Linley, M. Palomba, Catherine C Coombs, Jae H. Park, A. Zelenetz, L. Roeker, M. Rosendahl, D. E. Tsai, K. Ebata, B. Brandhuber, D. Hyman, I. Aifantis, A. Mato, Justin Taylor, O. Abdel-Wahab   +34 more
semanticscholar   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj   +1 more source

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024). [PDF]

Chin J Cancer Res
Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, Wu D, Zhang L, Miao L, Ma J, Zhu J, Jing H, Zhao R, Steering Committee OBOT, Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa TCPATESG, Chinese Pharmaceutical Association Cpa HPPCO, Chinese Pharmacological Society Cps DOTDMO, Clinical Oncology Csco ECOLOCSO, Chinese Society Of Clinical Oncology Csco ECOLO, China Anti-Cancer Association Caca SOICO, Chinese Medical Association Cma CSOHO, Cross-Straits Medicine Exchange Association Smea HPPCO.   +21 more
europepmc   +2 more sources

In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton's Tyrosine Kinase: Potential Drug Repurposing for Allergies. [PDF]

Cureus
Martinez-Martinez RE, Calva-Hernandez CI, Rodriguez-Lopez GM, Soria-Castro R, Ruiz-Sanchez BP, Chavez-Blanco AD, Pérez-Tapia SM, Pavano-Rodriguez CG, Chacon-Salinas R.   +8 more
europepmc   +3 more sources

Disrupting enzyme fluidity

eLife, 2021
A combination of X-ray crystallography, NMR, and mass spectrometry has revealed how diverse small-molecule inhibitors bind Bruton’s tyrosine kinase and alter the conformation of this enzyme.
Ganesh Srinivasan Anand
doaj   +1 more source

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
A Hochhaus, A Ptasznik, A Serrels, A Veldurthy, AC Shor, Alison M. McCaig, Alison M. Michie, AM McCaig, CD Allen, CM Pleiman, DY Hallaert, Emilio Cosimo, J Hoellenriegel, J Hoellenriegel, JA Burger, JA Burger, JA Burger, JW Friedberg, LJ Lombardo, M Buchner, M Burger, M Lopez-Guerra, M Niedermeier, M O'Hayre, MF de Rooij, Michael T. Leach, MP Quiroga, O Hantschel, P Ghia, PC Amrein, R Buettner, RE Hayden, S Braselmann, S Ponader, S Willimott, SJ Richardson, Spencer B. Gibson, Y Nakata, Z Song   +38 more
core   +7 more sources

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK

Frontiers in Cell and Developmental Biology, 2021
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description
Lauren E. Kueffer, Raji E. Joseph, Amy H. Andreotti   +2 more
doaj   +1 more source

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies.
Xianhui Wang, Leila Kokabee, Mostafa Kokabee, Douglas S. Conklin   +3 more
doaj   +1 more source

The role of Bruton's tyrosine kinase in the immune system and disease

Immunology, 2021
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and function, highlighted by its position as a critical component of the B‐cell receptor signalling pathway.
Charlotte McDonald, Charalambos Xanthopoulos, E. Kostareli   +2 more
semanticscholar   +1 more source